-
The Joint Commission says that "emergency medications and other interventions can help mitigate the impact of a [malignant hyperthermia (MH)] episode, but only if the needed materials are readily available and staff is adequately trained." Specifically, The Joint Commission requires:
-
At Ponte Vedra Plastic Surgery, cards were developed to explain the role of each of four nurses who handle malignant hyperthermia (MH) resuscitation.
-
When your patient develops malignant hyperthermia (MH), take these steps, providers suggest:
-
The report by the Palm Beach County Medical Examiner's Office regarding Florida teen Stephanie Kuleba, who died earlier this year of malignant hyperthermia (MH), doesn't answer all of the questions surrounding her death.
-
The cause of death in the case of a Florida teen having breast surgery has been confirmed as malignant hyperthermia (MH),1 and the eyes of the nation have turned to outpatient surgery providers and their preparation to handle an MH episode.
-
Outpatient surgery programs will have to look for physicians with a combination of skills before granting privileges for natural orifice surgery, says Marc Bessler, MD, director of laparoscopic surgery and director of Obesity Center, New York Presbyterian Hospital at Columbia University, New York City.
-
Identifying the best payers with whom to contract in your area can be done by researching local employers, but another way is to pay attention to what insurance cards you see from your patients.
-
(Editor's note: In the second part of a two-part series on contract negotiations, we give you tips for handling contract renewals, and we tell you how to identify the best potential contracts. In last month's issue, we told you what to do when your contact is up for renewal.)
-
The company Starbucks made a significant business decision a few months ago. Their board decided that they needed to focus on what they thought they did best: Operate as a specialty coffee store.
-
The FDA's amended rule for acceptance of foreign clinical studies not conducted under an investigational new drug (IND) application has drawn fire from health advocates who say it weakens ethical protections.